Acta Scientific Gastrointestinal Disorders (ASGIS)(ISSN: 2582-1091)

Case Report Volume 6 Issue 4

Microscopic Colitis and Rheumatoid Arthritis: What does this Duet Tell Us? Literature Review and Clinical Case

Gaukhar Bakhtiyarova* and Mehtap Tınazlı

Near East University Hospital, Faculty of Medicine, Department of Internal Medicine, Turkish Republic of Northern Cyprus, Nicosia, Cyprus

*Corresponding Author: Gaukhar Bakhtiyarova, Near East University Hospital, Faculty of Medicine, Department of Internal Medicine, Turkish Republic of Northern Cyprus, Nicosia, Cyprus.

Received: March 02, 2023; Published: March 23, 2023


RA is a chronic, autoimmune, systemic disease of unknown etiology that can cause joint deformities. In its treatment, non-steroidal anti-inflammatory drugs (NSAIDs), steroids, non-biological DMARDs and biological DMARDs are used in various combinations according to the degree and progression of the disease. NSAIDs are often used for a long time in combination with proton pump inhibitors (PPIs) because they act quickly and provide symptomatic relief. Microscopic colitis; It is a chronic bowel disease characterized by watery diarrhea. It is thought that the use of NSAII and PPI alone or together increases the risk of microscopic colitis. The primary disease itself and/or infection may also be triggers.

Keywords: Rheumatoid Arthritis; NSAID; PPI; Microscopic Colitis


  1. Miehlke S., et al. “Microscopic colitis: Pathophysiology and clinical management”. Lancet Gastroenterology and Hepatology 4 (2019): 305-314.
  2. Miehlke S., et al. “European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations”. United European Gastroenterology Journal 9 (2021): 13-37.
  3. Tome J., et al. “The Epidemiology of Microscopic Colitis in Olmsted County, Minnesota: Population-Based Study from 2011 to 2019”. Clinical Gastroenterology and Hepatology 20 (2022): 1085-1094.
  4. Gentile NM., et al. “The epidemiology of microscopic colitis in Olmsted County from 2002 to 2010: A population-based study”. Clinical Gastroenterology and Hepatology 12 (2014): 838-842.
  5. Andrews CN., et al. “Evaluation of endoscopist and pathologist factors affecting the incidence of microscopic colitis”. Canadian Journal of Gastroenterology 26 (2012): 515-520.
  6. Pardi DS. “Diagnosis and Management of Microscopic Colitis”. American Journal of Gastroenterology 112 (2017): 78-85.
  7. Rasmussen MA and Munck LK. “Systematic review: Are lymphocytic colitis and collagenous colitis two subtypes of the same disease-microscopic colitis?”. Alimentary Pharmacology and Therapeutics 36 (2012): 79-90.
  8. Sandler RS., et al. “Medication use and microscopic colitis”. Alimentary Pharmacology and Therapeutics 54 (2021): 1193-1201.
  9. Zylberberg HM., et al. “Medication use and microscopic colitis: A multicentre retrospective cohort study”. Alimentary Pharmacology and Therapeutics 53 (2021): 1209-1215.
  10. Bohr J., et al. “Diagnosis and management of microscopic colitis: Current perspectives”. Clinical and Experimental Gastroenterology 7 (2014): 273-284.
  11. Fernandez-Banares F., et al. “Drug consumption and the risk of microscopic colitis”. American Journal of Gastroenterology 102 (2007): 324-330.
  12. Guagnozzi D., et al. “Drug consumption and additional risk factors associated with microscopic colitis: Case-control study”. Revista Espanola De Enfermedades Digestivas 107 (2015): 347-353.
  13. Keszthelyi D., et al. “Proton pump inhibitor use is associated with an increased risk for microscopic colitis: A case-control study”. Alimentary Pharmacology and Therapeutics 32 (2010): 1124-1128.
  14. Nielsen OH., et al. “Microscopic colitis: a missed diagnosis?” The Lancet 364 (2004): 2055-2057.
  15. Escudero-Hernández C., et al. “Transcriptomic profiling of collagenous colitis identifies hallmarks of non destructive inflammatory bowel disease”. Cellular and Molecular Gastroenterology and Hepatology 12 (2021): 665-687.
  16. Marlicz W., et al. “Endoscopic findings and colonic perforation in microscopic colitis: A systematic review”. Digestive and Liver Disease 49 (2004): 1073-1085.
  17. P Verschueren., et al. “Debilitating diarrhea and weight loss due to colits in two RA patients treated with lenflunomide”. Clinical Rheumatology1 (2005): 87-90.
  18. Signe Wildt., et al. “Autoimmune disease in microscopic colitis: A Danish nationwide case-control study”. Alimentary Pharmacology and Therapeutics 54 (2021): 11-12.
  19. Bonderup OK., et al. “The epidemiology of microscopic colitis: A 10-year pathology-based nationwide Danish cohort study”. Scandinavian Journal of Gastroenterology 50 (2015): 393-398.
  20. Zahid Ijaz Tarar., et al. “Are Drugs Associated with Microscopic Colitis? A systematic Review and Meta -Analysis”. Diseases 11 (2023): 6.
  21. McInnes IB and O’Dell JR. “State-of-the art: rheumatoid arthritis”. Annals of the Rheumatic Diseases 69 (2010): 1898-906.
  22. Mohammed A., et al. “Quantifying risk factors for microscopic colitis: A nationwide, retrospective cohort study”. Indian Journal of Gastroenterology 41 (2022): 181-189.
  23. Verhaegh BP., et al. “High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors”. Alimentary Pharmacology and Therapeutics 43 (2016): 1004-1013.
  24. Weimers P., et al. “Microscopic Colitis in Denmark: Regional Variations in Risk Factors and Frequency of Endoscopic Procedures”. Journal of Crohn's and Colitis 16 (2022): 49-56.
  25. Masclee GM., et al. “Increased risk of microscopic colitis with use of proton pump inhibitors and non-steroidal anti-inflammatory drugs”. American Journal of Gastroenterology 110 (2015): 749-759.
  26. Imhann F., et al. “Proton pump inhibitors affect the gut microbiome”. Gut 65 (2016): 740-748.
  27. Lewis SJ., et al. “Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole”. Alimentary Pharmacology and Therapeutics 10 (1969): 557-561.
  28. Mullin JM., et al. “Proton pump inhibitors: Actions and reactions”. Drug Discovery Today 14 (2009): 647-660.
  29. Law EH., et al. “Association Between Proton Pump Inhibitors and Microscopic Colitis”. Annals of Pharmacotherapy 51 (2017): 253-263.
  30. Gleeson MH and Davis AJ. “Non-steroidal anti-inflammatory drugs, aspirin and newly diagnosed colitis: A case-control study”. Alimentary Pharmacology and Therapeutics 17 (2003): 817-825.
  31. Keszthelyi D., et al. “Is microscopic colitis a drug-induced disease?” Journal of Clinical Gastroenterology 46 (2012): 811-822.
  32. McInnes IB and O’Dell JR. “State-of-the art: rheumatoid arthritis”. Annals of the Rheumatic Diseases 69 (2010): 1898-906.
  33. Verstappen SM., et al. “A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up”. Annals of the Rheumatic Diseases 64 (2005): 38-43.
  34. Abignano G., et al. “Collagenous colitis in systemic sclerosis: an overlooked and treatable complication”. Journal of Clinical Rheumatology5 (2014): 278-282.
  35. Ekiz F., et al. “Collagenous colitis in a patient with systemic sclerosis: a rare entry”. Journal of the National Medical Association 99 (2007): 681-682.
  36. Michelle D Lundholm., et al. “Seronegative Adult Autoimmune Enteropathy in a patient with Rheumatoid Arthritis. Case report/colon”. ACG Case Report Journal 6 (2019): e00239.
  37. Istvan Fedor., et al. “Microscopic colitis in older adults: impact, diagnosis, and management”. Therapeutic Advances in Chronic Disease. Review 13 (2022): 1-15.
  38. Pardi DS and Kelly CP. “Microscopic colitis. (Reviews in basic and clinical gastroenterology and hepatology)”. Gastroenterology 140 (2011): 1155-1165.
  39. Bohr J., et al. “Auto antibodies and immunoglobulins in collagenous colitis”. Gut 39 (1996): 73-76.
  40. Freeman HJ. “Perinuclear antineutrohil cytoplasmic antibodies in collagenous or lymphocytic colitis with or without celiac disease”. Canadian Journal of Gastroenterology 11 (1997): 417-420.
  41. Ozaki H., et al. “Intestinal dysmotility in inflammatory bowel disease: Mechanisms of the reduced activity of smooth muscle contraction”. Inflammopharmacology1-3 (2005): 103-111.
  42. , et al. “Microscopic colitis: A retrospective study of clinical presentation in 53 patients. Clinical Research”. World Journal of Gastroenterology 11.9 (2005): 1351-1355.
  43. Istvan Fedor., et al. “Microscopic colitis: controversies in clinical symptoms and autoimmune comorbidities”. Annals of Medicine1 (2021): 1279-1284.
  44. Microscopic colitis. Prof. Dr. Taylan Kav, Hacettepe University Faculty of Medicine, Department of Internal Medicine, Department of Gastroenterology, Ankara.


Citation: Gaukhar Bakhtiyarova and Mehtap Tınazlı. “Splenic Artery Aneurysm. A Rare Entity Case Report". Acta Scientific Gastrointestinal Disorders 6.4 (2023): 36-42.


Copyright: © 2023 Gaukhar Bakhtiyarova and Mehtap Tınazlı. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate35%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US